Financial Survey: Centogene (CNTG) and Its Competitors
Centogene (NASDAQ: CNTG) is one of 29 public companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Centogene to similar companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.
Institutional & Insider Ownership
8.3% of Centogene shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 13.4% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Centogene and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Centogene currently has a consensus target price of $21.50, indicating a potential upside of 18.20%. As a group, “Medical laboratories” companies have a potential upside of 22.34%. Given Centogene’s rivals higher probable upside, analysts clearly believe Centogene has less favorable growth aspects than its rivals.
This table compares Centogene and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Centogene and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Centogene||$54.64 million||-$23.36 million||-12.46|
|Centogene Competitors||$985.62 million||$50.20 million||36.22|
Centogene’s rivals have higher revenue and earnings than Centogene. Centogene is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Centogene rivals beat Centogene on 7 of the 12 factors compared.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.